Senti Bio to Present Data from Gene Circuit-Engineered Allogeneic CAR-NK Cell Therapy Pipeline at Upcoming Scientific Conferences
May 02, 2022 16:00 ET
|
Senti Bio
- Three ASGCT abstracts highlight new data related to application of gene circuit technology to enhance efficacy and safety of cancer-killing CAR-NK cells - - ISCT abstract describes scalable,...
Senti Bio to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 18, 2022 09:00 ET
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that co-founders Tim Lu, MD, PhD, Chief...
Senti Bio Presents New Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
April 08, 2022 13:00 ET
|
Senti Bio
- Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of allogeneic CAR-NK cells for the treatment of solid tumors - - CAR-NK cells armed with calibrated...
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
March 08, 2022 16:30 ET
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association...
Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
January 06, 2022 08:02 ET
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and...
Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies
December 20, 2021 07:05 ET
|
Senti Bio
- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common...
Senti Bio Highlights Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting
December 13, 2021 09:02 ET
|
Senti Bio
- Preclinical data demonstrates complete functionality of SENTI-202 OR+NOT Logic Gated gene circuits for the elimination of AML cancer cells while sparing healthy stem cells - - Presentation...
Senti Bio Highlights Colorectal Cancer Preclinical Data from Logic Gated CAR-NK Cell Program at 36th SITC Annual Meeting
November 12, 2021 16:46 ET
|
Senti Bio
- SENTI-401 engineered to target colorectal cancer cells while sparing healthy cells - - Preclinical proof-of-concept data suggest that Logic Gated gene circuits can be used in CAR-NK cells to...
Senti Bio to Present Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting
November 04, 2021 09:02 ET
|
Senti Bio
- Preclinical data demonstrates functionality of SENTI-202 OR/NOT Logic Gated gene circuits for the elimination of AML cells while sparing healthy cells - - SENTI-202 is one of several pipeline...
Senti Bio CEO Appointed to The Alliance for Regenerative Medicine 2022 Board of Directors
October 21, 2021 09:05 ET
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced that its co-founder and chief executive officer, Tim Lu, MD, PhD, has been...